AR108955A2 - Suspensión oftálmica acuosa de rebamipida cristalina - Google Patents
Suspensión oftálmica acuosa de rebamipida cristalinaInfo
- Publication number
- AR108955A2 AR108955A2 ARP170101857A ARP170101857A AR108955A2 AR 108955 A2 AR108955 A2 AR 108955A2 AR P170101857 A ARP170101857 A AR P170101857A AR P170101857 A ARP170101857 A AR P170101857A AR 108955 A2 AR108955 A2 AR 108955A2
- Authority
- AR
- Argentina
- Prior art keywords
- aqueous solution
- rebamipide
- surfactants
- compounds selected
- soluble polymers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Un producto oftálmico que contiene rebamipida, el cual posee la suficiente transparencia como para tener una buena sensación en el uso y posee un pH neutro a débilmente ácido para no lesionar la queratoconjuntiva de un paciente que sufre de ojo seco. Se provee una suspensión acuosa de rebamipida cristalina que posee una transparencia mejorada por agregado de una solución acuosa de rebamipida disuelta por una base tal como hidróxido de sodio o una solución acuosa de una sal de rebamipida a una solución acuosa ácida tal como ácido clorhídrico que contiene por lo menos uno de los compuestos seleccionados de los polímeros solubles en agua y agentes tensioactivos, y mezclar los mismos. Reivindicación 1: Una suspensión acuosa de rebamipida cristalina caracterizada porque comprende una mezcla de (1) por lo menos uno de los compuestos seleccionados de polímeros solubles en agua y agentes tensioactivos, (2) una solución acuosa ácida, y (3) una solución acuosa que contiene una sal de rebamipida soluble en agua, donde la forma de la rebamipida cristalina es un cristal de aguja regular que tiene una longitud de calibre largo menor de 1000 nm y una longitud de calibre corto menor de 60 nm con la provisión que la relación entre la distancia larga de calibre y la distancia corta de calibre no sea menor que 4, la cual es preparada por (i) mezclar una solución acuosa ácida conteniendo al menos uno de los compuestos seleccionados de polímeros solubles en agua y agentes tensioactivos, y una solución acuosa conteniendo una sal de rebamipida soluble en agua, o (ii) mezclar una solución acuosa ácida y una solución acuosa conteniendo una sal de rebamipida soluble en agua y al menos uno de los compuestos seleccionados de polímeros solubles en agua y agentes tensioactivos, o (iii) mezclar una solución acuosa ácida conteniendo al menos uno de los compuestos seleccionados de polímeros solubles en agua y agentes tensioactivos, y una solución acuosa conteniendo una sal de rebamipida soluble en agua y al menos uno de los compuestos seleccionados de polímeros solubles en agua y agentes tensioactivos, y entonces ajustar el pH de la suspensión acuosa a 5 - 7 con una base.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004330140 | 2004-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108955A2 true AR108955A2 (es) | 2018-10-10 |
Family
ID=36336674
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104503A AR052779A1 (es) | 2004-11-15 | 2005-10-27 | Suspension oftalmica acuosa de rebamipida cristalina |
ARP170101857A AR108955A2 (es) | 2004-11-15 | 2017-07-05 | Suspensión oftálmica acuosa de rebamipida cristalina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050104503A AR052779A1 (es) | 2004-11-15 | 2005-10-27 | Suspension oftalmica acuosa de rebamipida cristalina |
Country Status (16)
Country | Link |
---|---|
US (2) | US9211254B2 (es) |
EP (1) | EP1812000A4 (es) |
JP (3) | JP4934587B2 (es) |
KR (1) | KR101271959B1 (es) |
CN (1) | CN100594901C (es) |
AR (2) | AR052779A1 (es) |
AU (1) | AU2005302908B2 (es) |
BR (1) | BRPI0518928A2 (es) |
CA (1) | CA2584017C (es) |
HK (1) | HK1112718A1 (es) |
MX (1) | MX2007005782A (es) |
MY (1) | MY152867A (es) |
RU (1) | RU2398585C2 (es) |
SG (1) | SG156692A1 (es) |
TW (1) | TWI363626B (es) |
WO (1) | WO2006052018A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200808375A (en) * | 2006-05-12 | 2008-02-16 | Otsuka Pharma Co Ltd | Hydrogel suspension and manufacturing process thereof |
TWI415629B (zh) | 2006-10-26 | 2013-11-21 | Otsuka Pharma Co Ltd | 含有瑞巴匹特之水性醫藥懸浮物及其製造方法 |
WO2008074853A1 (en) * | 2006-12-21 | 2008-06-26 | Novartis Ag | Ophthalmic rebamipide solution |
KR20110027786A (ko) * | 2008-06-19 | 2011-03-16 | 오츠카 세이야쿠 가부시키가이샤 | 레바미피드를 함유하는 의약 조성물 |
US9775802B2 (en) | 2009-03-24 | 2017-10-03 | Bausch & Lomb Incorporated | Method for preparing suspensions of low-solubility materials |
US20100247666A1 (en) * | 2009-03-24 | 2010-09-30 | Macleod Steven K | Method for Preparing Suspensions of Low-Solubility Materials |
AU2012232062B2 (en) * | 2011-03-24 | 2017-04-20 | Otsuka Pharmaceutical Co., Ltd. | A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide |
TW201322982A (zh) * | 2011-11-01 | 2013-06-16 | Otsuka Pharma Co Ltd | 用於治療前眼疾病之藥劑,該藥劑包含瑞巴派特及眼淚保持劑 |
SA113340675B1 (ar) * | 2012-06-26 | 2015-08-16 | استيش. كو.، ليمتد | أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها |
KR101692578B1 (ko) | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
EP2996673A1 (en) * | 2013-05-16 | 2016-03-23 | Universiteit Antwerpen | Thermolabile drug release formulation |
TWI697337B (zh) * | 2013-08-07 | 2020-07-01 | 學校法人近畿大學 | 奈米粒子或奈米粒子組成物之製造方法,及支架或球囊導管之製造方法 |
CN104586762A (zh) * | 2014-04-11 | 2015-05-06 | 广州仁恒医药科技有限公司 | 含有瑞巴派特的药物组合物及其制备方法 |
JP6854587B2 (ja) * | 2015-04-17 | 2021-04-07 | ロート製薬株式会社 | 医薬製剤 |
KR101718733B1 (ko) * | 2015-08-21 | 2017-03-22 | 국제약품 주식회사 | 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제 |
KR20170039347A (ko) * | 2015-10-01 | 2017-04-11 | 삼진제약주식회사 | 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법 |
KR102307958B1 (ko) | 2015-10-01 | 2021-10-05 | 삼진제약주식회사 | 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법 |
JP6732441B2 (ja) * | 2015-12-11 | 2020-07-29 | ロート製薬株式会社 | 局所粘膜適用水性組成物 |
KR101840256B1 (ko) * | 2017-09-21 | 2018-03-21 | 대우제약 주식회사 | 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법 |
KR101923519B1 (ko) | 2018-06-26 | 2019-02-27 | 대우제약 주식회사 | 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법 |
KR20200019451A (ko) | 2018-08-14 | 2020-02-24 | 대우제약 주식회사 | 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법 |
KR102615076B1 (ko) * | 2021-07-14 | 2023-12-19 | 대우제약 주식회사 | 안정한 레바미피드 점안제의 대용량 제조 방법 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS50121414A (es) | 1974-02-18 | 1975-09-23 | ||
JPS55139319A (en) | 1979-04-13 | 1980-10-31 | Furointo Sangyo Kk | Activation of drug soluble in alkali and acid |
JP2808378B2 (ja) * | 1991-03-27 | 1998-10-08 | 武田薬品工業株式会社 | 水性懸濁液剤の製造法 |
CA2083842A1 (en) | 1991-03-27 | 1992-09-28 | Hisayuki Nakayama | Method for preparation of an aqueous suspension |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5716642A (en) | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
AR004214A1 (es) * | 1995-10-12 | 1998-11-04 | Otsuka Pharma Co Ltd | Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas |
JP3093661B2 (ja) * | 1995-10-12 | 2000-10-03 | 大塚製薬株式会社 | 眼疾患治療剤 |
JPH09301855A (ja) * | 1996-05-13 | 1997-11-25 | Fuairudo Kk | 健康用部材 |
CA2289618A1 (en) | 1997-05-14 | 1998-11-19 | Shin-Ichi Yasueda | Aqueous suspension preparations with excellent redispersibility |
JP3402195B2 (ja) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
GB9810859D0 (en) * | 1998-05-20 | 1998-07-22 | Zeneca Ltd | Crystallisation process |
EP2591806A1 (en) * | 2001-06-14 | 2013-05-15 | Otsuka Pharmaceutical Co., Ltd. | Medicinal composition |
-
2005
- 2005-10-26 TW TW094137417A patent/TWI363626B/zh not_active IP Right Cessation
- 2005-10-27 AR ARP050104503A patent/AR052779A1/es not_active Application Discontinuation
- 2005-10-28 MY MYPI20055098 patent/MY152867A/en unknown
- 2005-11-11 CN CN200580038786A patent/CN100594901C/zh not_active Expired - Fee Related
- 2005-11-11 AU AU2005302908A patent/AU2005302908B2/en not_active Ceased
- 2005-11-11 RU RU2007122392/15A patent/RU2398585C2/ru not_active IP Right Cessation
- 2005-11-11 BR BRPI0518928-4A patent/BRPI0518928A2/pt not_active IP Right Cessation
- 2005-11-11 CA CA2584017A patent/CA2584017C/en not_active Expired - Fee Related
- 2005-11-11 KR KR1020077013372A patent/KR101271959B1/ko not_active IP Right Cessation
- 2005-11-11 WO PCT/JP2005/021178 patent/WO2006052018A1/en active Application Filing
- 2005-11-11 MX MX2007005782A patent/MX2007005782A/es active IP Right Grant
- 2005-11-11 US US11/667,313 patent/US9211254B2/en not_active Expired - Fee Related
- 2005-11-11 SG SG200907285-1A patent/SG156692A1/en unknown
- 2005-11-11 JP JP2007522862A patent/JP4934587B2/ja not_active Expired - Fee Related
- 2005-11-11 EP EP05806737A patent/EP1812000A4/en not_active Withdrawn
-
2008
- 2008-02-14 HK HK08101628.0A patent/HK1112718A1/xx not_active IP Right Cessation
-
2011
- 2011-12-27 JP JP2011286557A patent/JP2012092139A/ja active Pending
-
2014
- 2014-01-06 JP JP2014000138A patent/JP2014077012A/ja active Pending
-
2015
- 2015-10-19 US US14/887,222 patent/US9533052B2/en not_active Expired - Fee Related
-
2017
- 2017-07-05 AR ARP170101857A patent/AR108955A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1812000A1 (en) | 2007-08-01 |
TW200621252A (en) | 2006-07-01 |
US9533052B2 (en) | 2017-01-03 |
CA2584017A1 (en) | 2006-05-18 |
JP2012092139A (ja) | 2012-05-17 |
RU2007122392A (ru) | 2008-12-20 |
HK1112718A1 (en) | 2008-09-12 |
TWI363626B (en) | 2012-05-11 |
AU2005302908A1 (en) | 2006-05-18 |
US20070287729A1 (en) | 2007-12-13 |
KR101271959B1 (ko) | 2013-06-10 |
WO2006052018A1 (en) | 2006-05-18 |
CN100594901C (zh) | 2010-03-24 |
SG156692A1 (en) | 2009-11-26 |
EP1812000A4 (en) | 2012-08-08 |
KR20070092965A (ko) | 2007-09-14 |
JP2014077012A (ja) | 2014-05-01 |
US9211254B2 (en) | 2015-12-15 |
JP4934587B2 (ja) | 2012-05-16 |
JP2008519759A (ja) | 2008-06-12 |
CA2584017C (en) | 2013-08-27 |
CN101056636A (zh) | 2007-10-17 |
AU2005302908B2 (en) | 2011-03-31 |
MY152867A (en) | 2014-11-28 |
AR052779A1 (es) | 2007-04-04 |
MX2007005782A (es) | 2007-07-19 |
RU2398585C2 (ru) | 2010-09-10 |
BRPI0518928A2 (pt) | 2008-12-16 |
US20160101183A1 (en) | 2016-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR108955A2 (es) | Suspensión oftálmica acuosa de rebamipida cristalina | |
BRPI0609711B8 (pt) | uso de uma solução aquosa com potencial redutivo oxidativo (orp) | |
ES2125377T3 (es) | Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina. | |
AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
AR084285A1 (es) | Composiciones inmunogenicas | |
PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
AR062400A1 (es) | Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica | |
BR112012017994B8 (pt) | composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio | |
MY138185A (en) | Emulsfiers for drilling fluids | |
ES2509966T1 (es) | Composiciones que tienen concentraciones incrementadas de carboximetilcelulosa | |
EA201300535A1 (ru) | Водный раствор амброксола | |
RU2014153024A (ru) | Способ получения простых полиэфирполиолов | |
ES2101004T3 (es) | Formulacion estable de sales del enalapril, procedimiento para su preparacion y su uso. | |
EA201000612A1 (ru) | Антагонисты cgrp-пептиды | |
EA201170101A1 (ru) | Фармацевтические композиции роувастатина кальция | |
FR2412611A1 (fr) | Granules d'activateur de blanchiment | |
EA200801875A1 (ru) | Антагонист cd 80 | |
ID27253A (id) | Penggunaan turunan-turunan kampotesin dengan toksisitas gastrointestinal yang tereduksi | |
EA201070194A1 (ru) | Стабильная жидкая фармацевтическая композиция на основе тразодона | |
PA8576601A1 (es) | Formulacion parenteral liquida estable de parecoxib | |
AR043037A1 (es) | Benzo [1,2,5] tiadiazoles y su uso farmaceutico | |
UY31589A1 (es) | Derivados 6-heterociclico-imidazo[1,2-a]piridina-2-carboxamidas, su preparacion y su aplicacion en terapéutica | |
BRPI0411186A (pt) | composição de sabão lìquido transparente e processo para a preparação da mesma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |